NHS Scotland approves new therapies for paediatric insomnia, type 1 diabetes and post-menopausal symptoms

  • Scottish Medicines Consortium
  • 9 Sep 2019

  • curated by Pavankumar Kamat
  • UK Medical News
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

The Scottish Medicines Consortium (SMC) recently published advice pertaining to the acceptance of three new therapies for use by NHS Scotland.

Melatonin prolonged-release (Slenyto) has been accepted for the treatment of insomnia in children and adolescents aged 2 to 18 years with autism spectrum disorder and/or Smith-Magenis syndrome, where measures to improve sleep hygiene have not been adequate. Evidence showed melatonin increased the total sleep time and sleep onset latency in this population compared with that in placebo.

Dapagliflozin (Forxiga) has been accepted for the treatment of inadequately controlled type 1 diabetes mellitus as an adjunct to insulin in adults having a body mass index of ≥27kg/m2 when optimal insulin therapy alone cannot adequately control the glycaemic level. Evidence showed dapagliflozin + insulin significantly improved glycaemic control compared with insulin alone.

Ospemifene (Senshio) has been accepted for the treatment of moderate-to-severe symptomatic vulvar and vaginal atrophy in post-menopausal women who are not suitable to receive local vaginal oestrogen therapy. Evidence showed ospemifene significantly improved physiological parameters, such as vaginal maturation index and vaginal pH, and patient-reported symptom scores for vaginal dryness and dyspareunia compared with placebo.